Cumberland Pharmaceuticals Inc. (CPIX) reported a 31% increase in net revenues for Q4 2025, totaling $13.7 million, despite a significant 29.5% decline in its share price since the earnings announcement. This revenue increase was primarily driven by strong demand for products like Kristalose ($3.1 million), Sancuso ($3.3 million), and the recently launched Talicia, which contributed $3.3 million.
Operating expenses rose to $15 million from $12 million in the year-ago period, and the company posted a net loss of $1.41 million, or 9 cents per diluted share, compared to a loss of $1.90 million, or 14 cents per diluted share, a year earlier. For the full year of 2025, net revenues reached $44.5 million, reflecting an 18% year-over-year growth, while the company ended the year with $76.8 million in total assets.
Cumberland’s strategic initiatives included a co-commercialization agreement with RedHill Biopharma for Talicia and international expansions for Vibativ in China and Mexico. The company also received FDA Fast Track designation for its pipeline candidate, ifetroban, following positive results from its Phase II study.
